Geron to Present at J.P. Morgan Annual Healthcare Conference
MENLO PARK, Calif., Jan 07, 2011 (BUSINESS WIRE) -- Geron Corporation (GERN)
today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive
officer, will present an update of the company's product development programs at
2:30 p.m. PT / 5:30 p.m. ET on Wednesday, January 12, 2011, at the 29th Annual
J.P. Morgan Healthcare Conference in San Francisco.
The presentation will provide an update on Geron's oncology programs, including
the telomerase inhibitor drug (imetelstat sodium - GRN163L), the telomerase
therapeutic vaccine (GRNVAC1) and the recently in-licensed compound designed to
penetrate the blood-brain barrier (GRN1005). The presentation will also include a
review of the company's human embryonic stem cell development programs for spinal
cord injury (GRNOPC1), heart disease (GRNCM1), diabetes (GRNIC1), and
osteoarthritis (GRNCHND1), and the telomerase activator program (GRN510).
The webcast link for the live audio and slide presentation will be available on
the Investors page of the company's website at
geron.com. The presentation will be
archived for replay and available at the same address one hour after conclusion
of the live event for a period of 30 days.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer
and chronic degenerative diseases. The company is advancing anti-cancer therapies
through multiple Phase 2 clinical trials in different cancers by targeting the
enzyme telomerase and with a compound designed to penetrate the blood-brain
barrier (BBB). The company is developing cell therapy products from
differentiated human embryonic stem cells for multiple indications, including
central nervous system (CNS) disorders, heart failure, diabetes and
osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury.
For more information, visit geron.com.
SOURCE: Geron Corporation
Geron Corporation
Anna Krassowska, Ph.D., 650-473-7765
Investor and Media Relations
info@geron.com |
